ARCHIVES

In Brief: Schepartz To Leave NCI for Academia; Woolley Names To Head Clinical Research At Lombardi

This article is from The Cancer Letter archive.

Vol. 10 No. 10 | March 9, 1984

Download PDF Visit The Full Archive

Related Articles

Glaxo, Mass General Begin Phase III Trial Of Tykerb

December 29, 2006

Recompetitions Of DCT Contracts Okayed

March 3, 1989

Mihich Recommendation for Antigen Development In BRMP Summarized

December 14, 1979

Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival

December 27, 2013

NCI Study Finds No Greater Cancer Risk Near Nuclear Plants

September 28, 1990

Two New Therapies For Metastatic Cancer Highlighted At AACR Annual Meeting

August 29, 2003